Other Events ·
Virax Biolabs Group Limited is holding an Extraordinary General Meeting on August 14, 2026, to seek shareholder…
VRAXVirax Biolabs Group Ltd
Virax Biolabs Group Limited is holding an Extraordinary General Meeting on August 14, 2026, to seek shareholder approval for increasing its authorized share capital from US$50,000 (2 million shares) to US$12.5 million (500 million shares). This creation of 498 million new ordinary shares is intended to provide funding and transactional flexibility for operations and business development related to ViraxImmune™. The company will also adopt a Fifth Amended and Restated Memorandum and Articles of Association to reflect this capital increase. Virax Biolabs Group Limited operates in the biotechnology industry, focusing on viral vector manufacturing and vaccine development.